Compare HSCS & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSCS | ASBP |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.8M |
| IPO Year | N/A | N/A |
| Metric | HSCS | ASBP |
|---|---|---|
| Price | $2.63 | $6.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 208.8K |
| Earning Date | 03-16-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.05 |
| 52 Week High | $4.39 | $7.05 |
| Indicator | HSCS | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 53.40 |
| Support Level | $2.61 | $4.29 |
| Resistance Level | $3.18 | $6.98 |
| Average True Range (ATR) | 0.41 | 0.67 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 48.77 | 70.75 |
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.